[Optimizing the therapy of symptomatic partial epilepsy with sustained release carbamazepine].
This article summarizes a three-year experience of treating 34 patients with carbamazepine (CMZ) retard with partial epilepsy who had previously been treated with a standard form of CMZ. The following steps were taken in order to optimize the therapy: the usage of monotherapy with CMZ, an increase of CMZ dose if it was necessary, usage of CMZ retard-form. Increase of the dose (more than 1400 mg) resulted in adverse reactions in 6 patients, which regressed when the patients started to be treated with CMZ retard form. On the whole, optimization of therapy provided the following effects: 18 patients (53%) did not experience any seizures, in 11 patients (32%) a frequency of the seizures was considerably decreased (by 50% and more as compared with the baseline level). Individual analysis of the seizures frequency showed that in patients treated with CMZ retard-form the maximal decrease of this frequency was observed for sleep seizures. A frequency of seizures decreased by 63% at night and by 34% in day hours.
Vorob'eva
O V
OV
D000293:Adolescent; D000328:Adult; D000927:Anticonvulsants / Q000008:administration & dosage / Q000627:therapeutic use*; D002220:Carbamazepine / Q000008:administration & dosage / Q000627:therapeutic use*; D003692:Delayed-Action Preparations; D004828:Epilepsies, Partial / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
D000927:Anticonvulsants; D003692:Delayed-Action Preparations; D002220:Carbamazepine